Evaluating the effect of curcumex supplement on the symptoms of patients with COVID-19
Phase 2
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20230125057216N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
ground glass opacity in lung CT scan
Clinical symptoms such as dry cough- dyspnea-fever- weakness- diarrhea- headache-rhinorrhea- or history of contact with COVID19 patient or recent travel to high-risk areas
Positive Covid-19PCR
Exclusion Criteria
PO intolerance
Dissatisfaction for Participation in research
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigation of the improvement rate of clinical symptoms of patients including cough, dyspnea, weakness, fever and diarrhea one month after take medication. Timepoint: At the beginning of the study and one month later. Method of measurement: history and physical examination.
- Secondary Outcome Measures
Name Time Method White blood cell counts. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data.;ESR. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data.;CRP. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data.;Comparison of the effect of Curcumex treatment on changes in serum creatinine. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data.;Comparison of the effect of Curcumex treatment on changes in liver enzymes. Timepoint: At the beginning of the study and after 30 days from the start of taking medication. Method of measurement: lab data.